Sangamo BioSciences Inc. (SGMO) Shares Up 2.2%
Sangamo BioSciences Inc. (NASDAQ:SGMO) shares shot up 2.2% during mid-day trading on Friday . The company traded as high as $4.30 and last traded at $4.27, with a volume of 360,775 shares trading hands. The stock had previously closed at $4.18.
A number of brokerages have recently issued reports on SGMO. Jefferies Group reiterated a “buy” rating and set a $14.00 target price on shares of Sangamo BioSciences in a research report on Thursday, June 9th. Janney Montgomery Scott lowered Sangamo BioSciences from a “buy” rating to a “neutral” rating and decreased their target price for the company from $15.00 to $8.00 in a research report on Thursday, August 4th. Wells Fargo & Co. began coverage on Sangamo BioSciences in a research report on Tuesday, May 3rd. They set a “buy” rating on the stock. Zacks Investment Research lowered Sangamo BioSciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th. Finally, Wedbush reiterated an “outperform” rating and set a $30.00 target price on shares of Sangamo BioSciences in a research report on Friday, May 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. Sangamo BioSciences presently has a consensus rating of “Buy” and a consensus price target of $15.58.
The company’s 50-day moving average is $5.30 and its 200-day moving average is $5.88. The stock’s market capitalization is $302.25 million.
Sangamo BioSciences (NASDAQ:SGMO) last released its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.14. The firm earned $3.70 million during the quarter, compared to analyst estimates of $5.38 million. During the same quarter in the prior year, the firm posted ($0.17) earnings per share. The company’s revenue for the quarter was down 56.0% on a year-over-year basis. On average, analysts predict that Sangamo BioSciences Inc. will post ($1.11) earnings per share for the current year.
Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.